Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069715 | 0.84 | DRD2 (0.45) | DRD2CHRM1KDM5ASMYD3ALDH1A1 | |
| SCHEMBL20147474 | 0.79 | KDM5A (0.44) | DRD2CHRM1KDM5AALDH1A1 | |
| SCHEMBL20069694 | 0.77 | KDM5A (0.45) | DRD2CHRM1KDM5ASMYD3ALDH1A1 | |
| SCHEMBL17672878 | 0.75 | KDM5A (0.52) | DRD2CHRM1KDM5ASMYD3ALDH1A1 | |
| SCHEMBL17848797 | 0.74 | PTPN2 (0.48) | CHRM1KDM5AHPGD | |
| SCHEMBL20224884 | 0.74 | POLB (0.46) | DRD2CHRM1KDM5AALDH1A1POLB | |
| SCHEMBL22856999 | 0.73 | DRD2 (0.46) | DRD2CHRM1KDM5AALDH1A1RET | |
| SCHEMBL20147472 | 0.73 | KDM5A (0.48) | DRD2CHRM1KDM5A | |
| Hydrochloric Acid SCHEMBL17848602 | 0.73 | POLB (0.44) | DRD2CHRM1KDM5AALDH1A1POLB | |
| SCHEMBL22856996 | 0.72 | EPHX1 (0.41) | CHRM1ALDH1A1POLBRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | DRD2 3425/4885CHRM1 2035/4885KDM5A 902/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | DRD2 3425/4885CHRM1 2035/4885KDM5A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.